tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Feb 20;9(5)
fac066.
doi: 10.1093/ofid/ofac066. eCollection 2022 May.
Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms
Carolyn T Bramante[SUP] 1 [/SUP], Jennifer L Proper[SUP] 2 [/SUP], David R Boulware[SUP] 3 [/SUP], Amy B Karger[SUP] 4 [/SUP], Thomas Murray[SUP] 2 [/SUP], Via Rao[SUP] 1 [/SUP], Aubrey Hagen[SUP] 1 [/SUP], Christopher J Tignanelli[SUP] 5 [/SUP], Michael Puskarich[SUP] 6 [/SUP], Ken Cohen[SUP] 7 [/SUP], David M Liebovitz[SUP] 8 [/SUP], Nichole R Klatt[SUP] 5 [/SUP], Courtney Broedlow[SUP] 5 [/SUP], Katrina M Hartman[SUP] 1 [/SUP], Jacinda Nicklas[SUP] 9 [/SUP], Sherehan Ibrahim[SUP] 1 [/SUP], Adnin Zaman[SUP] 9 [/SUP], Hanna Saveraid[SUP] 1 [/SUP], Hrishikesh Belani[SUP] 10 [/SUP], Nicholas Ingraham[SUP] 11 [/SUP], Grace Christensen[SUP] 1 [/SUP], Lianne Siegel[SUP] 2 [/SUP], Nancy E Sherwood[SUP] 12 [/SUP], Regina Fricton[SUP] 8 [/SUP], Sam Lee[SUP] 8 [/SUP], David J Odde[SUP] 13 [/SUP], John B Buse[SUP] 14 [/SUP], Jared D Huling[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Data conflict on whether vaccination decreases severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load. The objective of this analysis was to compare baseline viral load and symptoms between vaccinated and unvaccinated adults enrolled in a randomized trial of outpatient coronavirus disease 2019 (COVID-19) treatment.
Methods: Baseline data from the first 433 sequential participants enrolling into the COVID-OUT trial were analyzed. Adults aged 30-85 with a body mass index (BMI) ≥25 kg/m[SUP]2[/SUP] were eligible within 3 days of a positive SARS-CoV-2 test and <7 days of symptoms. Log[SUB]10[/SUB] polymerase chain reaction viral loads were normalized to human RNase P by vaccination status, by time from vaccination, and by symptoms.
Results: Two hundred seventy-four participants with known vaccination status contributed optional nasal swabs for viral load measurement: median age, 46 years; median (interquartile range) BMI 31.2 (27.4-36.4) kg/m[SUP]2[/SUP]. Overall, 159 (58%) were women, and 217 (80%) were White. The mean relative log[SUB]10[/SUB] viral load for those vaccinated <6 months from the date of enrollment was 0.11 (95% CI, -0.48 to 0.71), which was significantly lower than the unvaccinated group (P = .01). Those vaccinated ≥6 months before enrollment did not differ from the unvaccinated with respect to viral load (mean, 0.99; 95% CI, -0.41 to 2.40; P = .85). The vaccinated group had fewer moderate/severe symptoms of subjective fever, chills, myalgias, nausea, and diarrhea (all P < .05).
Conclusions: These data suggest that vaccination within 6 months of infection is associated with a lower viral load, and vaccination was associated with a lower likelihood of having systemic symptoms.
Keywords: SARS-CoV-2; symptoms; vaccines; viral load.
. 2022 Feb 20;9(5)
fac066.doi: 10.1093/ofid/ofac066. eCollection 2022 May.
Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms
Carolyn T Bramante[SUP] 1 [/SUP], Jennifer L Proper[SUP] 2 [/SUP], David R Boulware[SUP] 3 [/SUP], Amy B Karger[SUP] 4 [/SUP], Thomas Murray[SUP] 2 [/SUP], Via Rao[SUP] 1 [/SUP], Aubrey Hagen[SUP] 1 [/SUP], Christopher J Tignanelli[SUP] 5 [/SUP], Michael Puskarich[SUP] 6 [/SUP], Ken Cohen[SUP] 7 [/SUP], David M Liebovitz[SUP] 8 [/SUP], Nichole R Klatt[SUP] 5 [/SUP], Courtney Broedlow[SUP] 5 [/SUP], Katrina M Hartman[SUP] 1 [/SUP], Jacinda Nicklas[SUP] 9 [/SUP], Sherehan Ibrahim[SUP] 1 [/SUP], Adnin Zaman[SUP] 9 [/SUP], Hanna Saveraid[SUP] 1 [/SUP], Hrishikesh Belani[SUP] 10 [/SUP], Nicholas Ingraham[SUP] 11 [/SUP], Grace Christensen[SUP] 1 [/SUP], Lianne Siegel[SUP] 2 [/SUP], Nancy E Sherwood[SUP] 12 [/SUP], Regina Fricton[SUP] 8 [/SUP], Sam Lee[SUP] 8 [/SUP], David J Odde[SUP] 13 [/SUP], John B Buse[SUP] 14 [/SUP], Jared D Huling[SUP] 2 [/SUP]
Affiliations
- PMID: 35392460
- PMCID: PMC8982774
- DOI: 10.1093/ofid/ofac066
Abstract
Background: Data conflict on whether vaccination decreases severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load. The objective of this analysis was to compare baseline viral load and symptoms between vaccinated and unvaccinated adults enrolled in a randomized trial of outpatient coronavirus disease 2019 (COVID-19) treatment.
Methods: Baseline data from the first 433 sequential participants enrolling into the COVID-OUT trial were analyzed. Adults aged 30-85 with a body mass index (BMI) ≥25 kg/m[SUP]2[/SUP] were eligible within 3 days of a positive SARS-CoV-2 test and <7 days of symptoms. Log[SUB]10[/SUB] polymerase chain reaction viral loads were normalized to human RNase P by vaccination status, by time from vaccination, and by symptoms.
Results: Two hundred seventy-four participants with known vaccination status contributed optional nasal swabs for viral load measurement: median age, 46 years; median (interquartile range) BMI 31.2 (27.4-36.4) kg/m[SUP]2[/SUP]. Overall, 159 (58%) were women, and 217 (80%) were White. The mean relative log[SUB]10[/SUB] viral load for those vaccinated <6 months from the date of enrollment was 0.11 (95% CI, -0.48 to 0.71), which was significantly lower than the unvaccinated group (P = .01). Those vaccinated ≥6 months before enrollment did not differ from the unvaccinated with respect to viral load (mean, 0.99; 95% CI, -0.41 to 2.40; P = .85). The vaccinated group had fewer moderate/severe symptoms of subjective fever, chills, myalgias, nausea, and diarrhea (all P < .05).
Conclusions: These data suggest that vaccination within 6 months of infection is associated with a lower viral load, and vaccination was associated with a lower likelihood of having systemic symptoms.
Keywords: SARS-CoV-2; symptoms; vaccines; viral load.
